MULTIFUNCTIONAL RNA MOLECULES TO TREAT EWING SARCOMA

Desarrollado por: Instituto de Investigación Biomédica de Bellvitge (IDIBELL)

Descripción

UNMET NEED:

Lack of prevention and effective treatments of Ewing Sarcoma (ES)

PROPOSED SOLUTION:

New conjugate to suppress ES progressive and metastasis capacity

FEATURES:

• New effective treatment for ES and other sarcomas

• Multifunctional RNA conjugate targeting Ewing Sarcoma metastasis

Aplicaciones

This technology will be mainly directed to treat Ewing Sarcoma.

Nevertheless, it could also be used in alveolar rhabdomyosarcomas (ARMS) and other sarcomas, since they area characterized by the presence of another chromosomal translocationand also have elevated levels of EphA2 receptor.

Estado de protección

Its therapeutic efficacy has been demonstrated in vitro in cell lines and is being demonstrated in vivo in animal models. The group also has proposed the possibility of expanding the use of the conjugate using different siRNAs against the fusion proteins characteristic of these sarcomas.

The therapeutic efficacy of the conjugate is being tested in an orthotopic ES model. The reproducibility of the conjugate in the ARMS is also being tested.

TRL: Animal Model Validation

IP: Patent in process

Cooperación que se desea

Co-development

License agreement

Investment

Responsable: Área de Desarrollo de Negocio e Innovación // Oficina de Transferencia de Tecnología

Contacto (Tel./mail): 93 260 71 06 / Innovacio@idibell.cat

Estado:
En desarrollo, Transferible
Tecnología sanitaria:
Biotecnología y Diagnóstico Molecular (proteómica, genómica, etc...), Medicamentos - Farma